We analyzed genomic data from the prostate cancer of African- and European American men to identify differences contributing to racial disparity of outcome. We also performed FISH-based studies of Chromodomain helicase DNA-binding protein 1 (CHD1) loss on prostate cancer tissue microarrays. We created CHD1-deficient prostate cancer cell lines for genomic, drug sensitivity and functional homologous recombination (HR) activity analysis. Subclonal deletion of CHD1 was nearly three times as frequent in prostate tumors of African American than in European American men and it associates with rapid disease progression. CHD1 deletion was not associated with HR deficiency associated mutational signatures or HR deficiency as detected by RAD51 foci formation. This was consistent with the moderate increase of olaparib and talazoparib sensitivity with several CHD1 deficient cell lines showing talazoparib sensitivity in the clinically relevant concentration range. CHD1 loss may contribute to worse disease outcome in African American men.
NPJ precision oncology. 2024 Sep 19*** epublish ***
Miklos Diossy, Viktoria Tisza, Hua Li, Pranshu Sahgal, Jia Zhou, Zsofia Sztupinszki, Denise Young, Darryl Nousome, Claire Kuo, Jiji Jiang, Yongmei Chen, Reinhard Ebner, Isabell A Sesterhenn, Joel T Moncur, Gregory T Chesnut, Gyorgy Petrovics, Gregory T Klus, Gabor Valcz, Pier Vitale Nuzzo, Dezso Ribli, Judit Börcsök, Aurel Prosz, Marcin Krzystanek, Thomas Ried, David Szuts, Kinza Rizwan, Salma Kaochar, Shailja Pathania, Alan D D'Andrea, Istvan Csabai, Shiv Srivastava, Matthew L Freedman, Albert Dobi, Sandor Spisak, Zoltan Szallasi
Danish Cancer Institute, Copenhagen, Denmark., Computational Health Informatics Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA., Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA., Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., CytoTest Inc., Rockville, MD, USA., Joint Pathology Center, Silver Spring, MD, USA., MTA-SE Molecular Medicine Research Group, Hungarian Academy of Sciences, Budapest, 1051, Hungary., Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Department of Physics of Complex Systems, Eötvös Loránd University, Budapest, Hungary., Genetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Institute of Molecular Life Sciences, HUN-REN Research Centre for Natural Sciences, Budapest, Hungary., Department of Medicine, Baylor College of Medicine, Houston, TX, USA., Center for Personalized Cancer Therapy, University of Massachusetts, Boston, MA, USA., Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. ., Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA. ., Institute of Molecular Life Sciences, HUN-REN Research Centre for Natural Sciences, Budapest, Hungary. ., Danish Cancer Institute, Copenhagen, Denmark. .